Virginia Vine

Early Detection

The 2022 Virginia Vine event is fundraising for early detection research. Funds raised for early detection research will be awarded to the nation’s best cancer researchers.

What is early detection?

Early detection focuses on identifying cancer symptoms as early as possible.

When cancer is found early, treatments are potentially more successful and may be less invasive. Treatments are also less expensive when cancer is discovered earlier.

Why does the V Foundation fund early detection research?

Certain cancers have improved outcomes if the cancer is detected early. Those cancers include: breast, lung, cervical, colon, pancreatic and ovarian, among others.

In 2018, there were more than 18 million new cases of cancer diagnosed, of which nearly 5 million cases of breast, cervical, colorectal, and oral cancers could have been detected sooner and treated more effectively.

The V Foundation has funded more than $3.8 million in early detection research.

Among the V Foundation researchers:

Jame Bakkum-Gamez, M.D., 2016 Translational Grant: Bakkum-Gamez and her team identified unique markers for the most common form of endometrial cancer, which tends to be the easiest to treat, as well as forms of endometrial cancer that are more aggressive. They are working on an at-home test for woman to use. If the larger clinical studies continue to be successful, Bakkum-Gamez estimates the at-home screening test could potentially be available in the next five years.

Amit Verma, M.D., 2013 Designated Grant: This study researched the connection between the environmental exposures at the World Trade Center site and first responders from 9/11 diagnosed with a type of bone marrow cancer called multiple myeloma. More information about the grant can be found here: /your-support-helps-diagnose-9-11-first-responders/

Guang-Shing Cheng, M.D., 2019 Translational Grant: Cheng developed a system to diagnose bronchiolitis obliterans syndrome (BOS) sooner. BOS is a debilitating side effect for a specific cancer treatment, and it is often diagnosed in an advanced state, making treatment difficult. Cheng and her team created a tool that can help a patient’s doctor diagnose and treat BOS earlier. Their goal is to ensure that patients who survive cancer also thrive after their treatment.